altana

(redirected from Byk Gulden)

altana

A light ornamental structure on a roof that serves much the same function as a gazebo.
Mentioned in ?
References in periodicals archive ?
Drug discovery alliance partners include: the ALTANA AG pharmaceuticals group Byk Gulden, Aventis Pharma, Boehringer Ingelheim International, Cell Genesys and MorphoSys.
Most recently, he was head of Global Regulatory Affairs and Scientific Information at Byk Gulden and Altana Pharma.
Drug discovery alliance partners include: Aventis Pharma, Bayer AG, DuPont Pharmaceuticals, Boehringer Ingelheim International GmbH, the Altana AG subsidiary Byk Gulden, Cell Genesys, Inc.
Drug discovery alliance partners include: Aventis Pharma (Bridgewater, NJ), DuPont Pharmaceuticals (Wilmington, DE), Boehringer-Ingelheim (Ingelheim, Germany), Byk Gulden, Cell Genesys, Inc.
DRG International - Byk Gulden - Biomerica - Princeton BioMeditech Corporation - Worldwide Medical Corporation - Abbott Diagnostics - Cytyc Corp.
ALTANA Pharma, formerly Byk Gulden, is an international pharmaceutical company focused primarily on respiratory and gastrointestinal treatments.
Abbott, ALKEM, Allen SpA, Apotex, Argenta, AstraZeneca, Aurex Generics, Aurobindo Pharma, Avecia, Pharmaceuticals, Baxter International, Biocon, Boots International, Boots Piramal, BYK Gulden, Cipla, Clonmel Healthcare, CP Pharmaceuticals, Cynamid, Divis Laboratories, Docpharma, Dr Reddy's Laboratories, Eli Lilly, Eon
In close collaboration with Byk Gulden Evotec OAI scientists have developed a new and complex assay programme using Evotec OAI's novel detection platform for high-throughput imaging (Opera).
Previously she was a Technical Director for Nycomed Amersham (Lausanne) and Head of Research at Byk Gulden Italia (Altana Pharma), Milan, Italy, where she developed sensitive blood assay systems to a commercial level, and obtained an FDA approval for a new contrast media injector.
Of that, GPC Biotech will receive US$ 60 million from Byk Gulden in committed funding under a collaboration and license agreement in the form of an upfront payment, technology license and implementation fees, as well as research and technology transfer funding.
Pantoprazole currently is available in over 60 countries and was first launched outside the US in 1994 by Byk Gulden of Konstanz, Germany, developers of the compound.